A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vitespen (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Jul 2006 Status change
- 14 Oct 2005 New trial record.